Navigation Links
USC and second sight announce European clinical trial for Argus II retinal implant
Date:2/15/2008

sity of Southern California (USC), Wilmer Eye Institute at Johns Hopkins University (Baltimore), the University of California at San Francisco, and the Retina Foundation of the Southwest (Dallas). Second Sight will be seeking expansion of the U.S. trial to include other trial sites located in New York (Columbia University Medical Center and Lighthouse International), Philadelphia (Scheie Eye Institute and Wills Eye Hospital) and Atlanta (Emory University and Atlanta V.A. Rehab R&D Center). This three-year Investigational Device Exemption (IDE) trial is the only long-term study of a retinal prosthesis currently being conducted anywhere in the world.

Internationally, the Argus II study began in Mexico in the fall of 2006 at Centro de Retina Medica y Quirurgica, SC, Centro Medico Puerta de Hierro, CUCS, Universidad de Guadalajara (Guadalajara, Jal.). More recently, enrollment has just begun at two European sites, including Service dOphtalmologie, Hpital Cantonal, Universitaire de Genve (Geneva, Switzerland) and Le Centre Hospitalier National DOphtalmologie Des Quinze-Vingts (Paris, France). A third study site at Moorfields Eye Hospital in London has recently received government approval and is expected to begin enrollment shortly.

The pioneering efforts of the individuals that participate in this clinical trial will lead to advances for the many people in the world afflicted with blindness, said Mark Humayun, MD, PhD, Professor of Ophthalmology, Biomedical Engineering, and Cellular and Neurobiology at the Doheny Eye Institute, Keck School of Medicine of USC, and Viterbi School of Engineering and the first physician to perform an Argus II implantation procedure in the US.

Dr. Humayun was the vitreo-retinal surgeon for the first generation 16-electrode (Argus 16), which he implanted in six RP subjects between 2002 and 2004. The study demonstrated the ability of participants to detect when lights are on or off, describe an objects motion, cou
'/>"/>

Contact: Jon Weiner
jon.weiner@usc.edu
323-442-2830
University of Southern California
Source:Eurekalert

1

GOOD

Page: 1 2 3

Related biology technology :

1. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
2. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
3. Escalon(R) Reports Second Quarter Fiscal 2008 Results
4. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
5. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
6. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
7. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
8. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008
9. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
10. Nutrition 21 to Report Second Quarter Fiscal 2008 Financial Results Monday, February 11, 2008
11. Neurobiological Technologies Sets Date for Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... SAN FRANCISCO , Feb. 9 /PRNewswire/ ... in Integrated Voice Response (IVR)/Integrated Web Response (IWR) ... platform that allows users to design and deploy ... 40 percent on the development time of clinical ... PULSE,s ability to provide pre-validated programs so developers ...
(Date:2/9/2010)... Md. , Feb. 9 ... today that it will release its fourth quarter ... on Tuesday, February 16, 2010 . ,, ... Tuesday, February 16, 2010 , at ... accessible by dialing 1-888-695-0608, with international callers dialing ...
(Date:2/8/2010)... February 8 QIAGEN,(NASDAQ: ... that its wholly,owned subsidiary DxS has acquired the ... Johns Hopkins University to develop real-time-PCR and,endpoint ... the PI3K gene could,be a key biomarker for ... The studies suggest that mutations in the PI3K ...
(Date:2/8/2010)... BEIJING , Feb. 8 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies,Inc. (the "Company") (Nasdaq: CMED ... at the,following investor conferences in March 2010 : , , Investor Conference ... Location, Rodman & Renshaw ... China Investment ... Beijing, Conference, Credit ...
Breaking Biology Technology:endpoint Saves Money and Time for Medical Research Teams Through PULSE 2endpoint Saves Money and Time for Medical Research Teams Through PULSE 3QIAGEN Acquires Exclusive Licence for Key PI3K gene 2QIAGEN Acquires Exclusive Licence for Key PI3K gene 3QIAGEN Acquires Exclusive Licence for Key PI3K gene 4China Medical Technologies to Participate Investor Conferences in March 2010 2
... Oncothyreon Inc. (Nasdaq: ONTY ) (TSX: ONY) ... investors to purchase approximately 3.88 million shares of its ... shares of its common stock for gross proceeds of ... the shares and warrants for $2.85 per unit (each ...
... (OTC Bulletin Board: MCLN) announced today that it has ... Company,s existing Common Stock Purchase Warrants with Initial Exercise ... ("Existing Warrants") for newly issued Common Stock Purchase Warrants, ... lesser number shares of our common stock, par value ...
... ROTTERDAM, Netherlands, May 19 InfraReDx, Inc. announced today the ... uses both light and sound to image coronary plaques. Working ... van der Ent performed the procedures on May 11, 2009 ... combination catheter provides the benefits of both IVUS and NIRS ...
Other Biology Technology:Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing 2MedClean Technologies, Inc. Announces Private Offer to Exchange Warrants 2MedClean Technologies, Inc. Announces Private Offer to Exchange Warrants 3MedClean Technologies, Inc. Announces Private Offer to Exchange Warrants 4First Use in Coronary Patients of a Combined Near-Infrared Spectroscopy and Ultrasound Imaging Catheter 2First Use in Coronary Patients of a Combined Near-Infrared Spectroscopy and Ultrasound Imaging Catheter 3
(Date:2/8/2010)... Feb. 8 With the recent election ... resulting in the loss of the Democratic supermajority, ... promise of universal coverage for the majority of uninsured ... Equity Research.  President Obama recently noted the country is ... has been for many a long sought after social ...
(Date:2/7/2010)... the National Cancer Institute (NCI) have found that the ... cancer among women without a personal history of breast ... the risk of developing breast cancer in women who ... of this survey are published in the February issue ... journal of the American Association for Cancer Research. ...
(Date:2/7/2010)... tricholorethylene (TCE), a chemical once widely used to clean ... significantly higher risk of developing Parkinson,s disease, according to ... the American Academy of Neurology,s 62nd Annual Meeting in ... is the first time a population-based study has confirmed ... person,s risk of developing Parkinson,s disease," said study author ...
Breaking Biology News(10 mins):S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 2S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 3S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 4S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 5S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 6S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 7S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 8S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 9Few women take tamoxifen to prevent breast cancer 2Ginkgo herbal medicines may increase seizures in people with epilepsy 65276 1One Type A Trait May Actually Lower Work Stress 65271 1FreightWatch Security Net Launches Solution for Tracking and Rescuing Persons at Risk of Wandering 65267 1FreightWatch Security Net Launches Solution for Tracking and Rescuing Persons at Risk of Wandering 65267 2FreightWatch Security Net Launches Solution for Tracking and Rescuing Persons at Risk of Wandering 65267 3FreightWatch Security Net Launches Solution for Tracking and Rescuing Persons at Risk of Wandering 65267 4
... team of Texas Agricultural Experiment Station scientists will ... to protect crops, which has implications for both ... Trichoderma virens, is used to protect field crops ... sequencing work may uncover chemical compounds and beneficial ...
... the first active vaccine that can significantly delay and possibly ... is similar to mad cow disease. The new findings, published ... platform for the development of a vaccine to prevent a ... called prions. , Although no cure for these diseases -- ...
... sub-Saharan Africa are threatened daily by a deadly parasitic ... caused by organisms called trypanosomes, which are spread by ... people in sub-Saharan Africa, a quarter of whom will ... genetic strategy for evading the human immune system and ...
Other Biology News:Experiment station researchers to explore genome of disease-fighting fungus 2Active Vaccine Prevents Mice From Developing Prion Disease 2Active Vaccine Prevents Mice From Developing Prion Disease 3Newly discovered protein an important tool for sleeping sickness research 2
acridine orange 10-nonyl bromide (nonyl acridine orange)...
Because it is manufactured at our ISO 9001–certified facilities in Eugene, Oregon, we can guarantee that FluoroPure grade propidium iodide is greater than or equal to 98% pure by HPLC....
MOUSE ANTI RAT RT1Bu Immunogen: Rat thymocyte membrane glycoproteins...
... of BAC (100+kb), fosmid (40kb), and large ... than any othe BAC vector. On command ... and easy recombinant DNA purification. Available with ... VC) vectors for the highest insert stability. ...
Biology Products: